Literature DB >> 9826186

Differential stimulation of proline-rich tyrosine kinase 2 and mitogen-activated protein kinase by sphingosine 1-phosphate.

C Guo1, C Zheng, I Martin-Padura, Z C Bian, J L Guan.   

Abstract

Sphingosine 1-phosphate (SphP), a metabolite of cellular sphingolipids, has been shown to induce cell proliferation by activating the mitogen-activated protein kinase (MAPK) pathway. Proline-rich tyrosine kinase 2 (Pyk2) is a novel cytosolic tyrosine kinase which mediates activation of the MAPK or c-Jun N-terminal kinase (JNK) signaling pathways in response to a variety of stimuli that elevate intracellular calcium. In this report, we show that SphP stimulates both tyrosine phosphorylation of Pyk2 and MAPK activation in a transient and dose-dependent manner in rat aortic smooth muscle cells. Further studies indicate that Pyk2 phosphorylation, but not MAPK activation, is dependent on a pertussis toxin-sensitive G-protein-coupled receptor as well as partially on actin cytoskeleton. In addition, both intracellular calcium mobilization and protein kinase C (PKC) are required for optimal Pyk2 phosphorylation while either calcium increase or PKC activation is sufficient for MAPK activation in response to SphP. Finally, we show that a tyrosine kinase(s) other than Pyk2 is necessary for MAPK activation by SphP. Together, these results suggest that SphP stimulates tyrosine phosphorylation of Pyk2 through a G-protein coupled receptor, which is dissociated from its activation of the MAPK pathway in these cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826186     DOI: 10.1046/j.1432-1327.1998.2570403.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  9 in total

Review 1.  Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease.

Authors:  S-K Jo; A Bajwa; A S Awad; K R Lynch; M D Okusa
Journal:  Kidney Int       Date:  2008-03-05       Impact factor: 10.612

Review 2.  Sphingosine 1-phosphate signalling in mammalian cells.

Authors:  S Pyne; N J Pyne
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

3.  Phospholipase D1 is threonine-phosphorylated in human-airway epithelial cells stimulated by sphingosine-1-phosphate by a mechanism involving Src tyrosine kinase and protein kinase Cdelta.

Authors:  Anna Ghelli; Anna M Porcelli; Annalisa Facchini; Silvana Hrelia; Flavio Flamigni; Michela Rugolo
Journal:  Biochem J       Date:  2002-08-15       Impact factor: 3.857

Review 4.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

5.  Sphingosine-1-phosphate stimulates human Caco-2 intestinal epithelial proliferation via p38 activation and activates ERK by an independent mechanism.

Authors:  Vijayalakshmi Thamilselvan; Wei Li; Bauer E Sumpio; Marc D Basson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-04       Impact factor: 2.416

6.  Pyk2 inhibitor prevents epithelial hyperpermeability induced by HMGB1 and inflammatory cytokines in Caco-2 cells.

Authors:  Takumi Konno; Takayuki Kohno; Maki Miyakawa; Hiroki Tanaka; Takashi Kojima
Journal:  Tissue Barriers       Date:  2021-03-04

7.  Regulation of gastric smooth muscle contraction via Ca2+-dependent and Ca2+-independent actin polymerization.

Authors:  Sunila Mahavadi; Ancy D Nalli; Hongxia Wang; Derek M Kendig; Molly S Crowe; Vijay Lyall; John R Grider; Karnam S Murthy
Journal:  PLoS One       Date:  2018-12-20       Impact factor: 3.240

8.  Cell aggregation induces phosphorylation of PECAM-1 and Pyk2 and promotes tumor cell anchorage-independent growth.

Authors:  Xing Zhang; Li-hua Xu; Qiang Yu
Journal:  Mol Cancer       Date:  2010-01-14       Impact factor: 27.401

9.  Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.

Authors:  B-H Kuang; M-Q Zhang; L-H Xu; L-J Hu; H-B Wang; W-F Zhao; Y Du; X Zhang
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.